Prescription medication use (other than antiretroviral therapy (ART)) is highly prevalent among people living with HIV. Prescription medications may be used medically or non-medically: nonmedical use includes using more medication than prescribed, using medication prescribed to someone else, or using medication for a purpose other than its prescribed use. During 12 weeks in 2014-2015, we characterized medical and non-medical prescription medication use among HIV-positive patients attending an academic medical center (n = 149) and a community clinic (n = 105). Separately for the past year and the past month, these 254 participants self-reported their use of prescription opioids, sedatives, stimulants, anti-anxiety medications, antipsychotic medications, and erectile dysfunction medications. Respondents were largely male (91%), aged 40 or older (61%), identified as gay or bisexual (79%), and were men who have sex with men (85%). ART use was nearly universal (95%). Nearly half (43%) of participants reported medical use of prescription opioids; 11% of the opioid use was reported as non-medical use. Anti-anxiety medication use was also frequent, and differed by site: 41% of community-clinic responders reported medical use of anti-anxiety medications compared to 23% of hospital clinic respondents who reported medical use. Prescription sedative use was also approximately twice as high among community-clinic participants, with medical use reported by 43% of respondents and non-medical use by 12%; in comparison, at the hospital clinic, sedative use was reported by 18% (medical) and 7% (non-medical) of participants. Stimulant use was rare in both sites. No demographic characteristic was significantly associated with medical or non-medical use of any prescription medication. The current focus of many studies on only non-medical prescription medication use not only underestimates the widespread exposure of HIV-positive individuals to these drugs, but may also underestimate potential adverse effects of prescription medications in this population.
Introduction
Use of illicit drugs such as heroin, cocaine, and methamphetamine has been associated with risky sexual behavior (Boone, Cook, & Wilson, 2013; Carey et al., 2009; Celentano, Latimore, & Mehta, 2008) . In people living with HIV type 1, illicit drug use has also been associated with reduced antiretroviral adherence (Colfax & Shoptaw, 2005; Hinkin et al., 2007; Horvath et al., 2013) . Although epidemiological studies linking illicit drug use to HIV disease progression have yielded mixed findings, laboratory studies have provided biologically plausible mechanisms to explain how certain illicit drugs may influence HIV disease progression (reviewed in Kapadia, Vlahov, Donahoe, & Friedland, 2005) .
Since the turn of the twenty-first century, patterns of drug use and abuse in the US have undergone a major shift (Johnston, O'Malley, Bachman, & Schulenberg, 2010) . A growing number of individuals now engage in both medical and non-medical use of prescription medications, including opioids (such as oxycodone), stimulants (such as dextroamphetamine), and central nervous system depressants (such as diazepam) (Kelly & Parsons, 2010; McCabe, Boyd, & Teter, 2009; Vijayaraghavan, Freitas, Bangsberg, Miaskowski, & Kushel, 2014) . Non-medical use of prescription drugs, which includes using more medication than prescribed, using medication prescribed to someone else, or using medication for a purpose other than its prescribed use, has been linked to risky sexual behavior (McCauley et al., 2010) . For example, men who have sex with men (MSM) who reported recent non-medical use of prescription drugs had more sex partners and more unprotected anal sex than MSM who did not misuse prescription medication (Benotsch, Martin, Koester, Cejka, & Luckman, 2011; Kelly & Parsons, 2010) .
To date, the sparse literature on prescription drug use among HIV-positive individuals has focused largely on non-medical use, and on HIV-positive populations recruited in higher risk environments. By measuring only non-medical use, the existing research likely underestimates overall exposure of HIV-positive individuals to prescription medications. In addition, because several prescription medications have almost identical pharmacology to illicit drugs, use of prescription medication could have effects on patient behavior and HIV disease progression similar to those of the use of illicit drugs. These effects would most likely correlate with the dose and duration of use of medication, but not with characterization of that use as medical or non-medical. Thus, to better understand the scope and magnitude of use of prescription medication in an "in care" population of people living with HIV, we characterized the prevalence of both medical and nonmedical prescription drug use among HIV-positive patients attending either an urban, academic medical center or community-based AIDS service organization.
Methods

Study setting, design and population
This cross-sectional, self-administered survey took place in two sites. The first site collected data during November 2014 and April 2015 in the infectious diseases clinic of a large, urban academic medical center (hereafter called hospital clinic). The second site collected data over a three-week period during July and August 2015 in a community-based AIDS service organization that provides HIV medical care and support services (hereafter called community clinic). Any patient aged 18 or older was eligible to participate. Staff gave the paper survey and an empty, unmarked envelope to all patients at registration. Patients were informed that their responses would not be shared with their medical providers, and were instructed not to write their names or other identifying information on the form or envelope. After completion, each participant placed the completed survey in the envelope and deposited it in a locked, metal box in the clinic. No additional recruitment was performed, no personal identifiers were collected, and no compensation was provided. Given this design, we did not collect information on the number of potential participants who declined to complete the survey. Of the 233 people who completed the survey at the hospital clinic, 149 were HIV-positive by self-report and are included in the analysis population. Of the 126 people who completed the survey at the community clinic, 105 were HIV-positive and were included in the analysis; the remainder were HIV-negative individuals seeking HIV testing services or HIV pre-exposure prophylaxis.
Measures
We first asked participants about their use of medications that had been prescribed to them by a medical provider (survey available upon request). We asked about use of each category of medication prescribed in the preceding 12 months and in the preceding 1 month, and we specified that these questions were assessing actual use of medication and not simply the receipt of a prescription for the medication. Specific medication categories queried included prescription sleep aids or sedatives (e.g., Ambien, Amytal, Numbutal, Seconal), attention deficit/hyperactivity disorder (ADD or ADHD) medications (e.g., Ritalin, Adderall, Concerta), panic or anxiety medications (e.g., Valium, Xanax, Klonopin, Halcion, Librium, Tranxene, Ativan, and Serax), antipsychotic medications (e.g., Zyprexa, Seroquel, and Haldol), erectile dysfunction medications (e.g., Viagra (blue pills, blue), Cialis, and Levitra), and opioid pain medications (e.g., OxyContin (oxy, cotton), Percocet (percs), Vicodin (vikes, Vikings), and Codeine). Next, we asked about the same list of medications, but specifically about their non-medical use. Finally, we asked participants about their use of other legal (alcohol, tobacco) and illegal drugs (marijuana, methamphetamine, 3,4-methylenedioxy-methamphetamine (MDMA), heroin, cocaine (including crack cocaine), "bath salts", poppers, rohypnol, mephedrone, ketamine, and Gamma-hydroxybutyrate).
Data management and analysis
Responses from paper surveys were entered into a database and imported into SAS (Version 9.4, Cary NC) for analysis. We used descriptive statistics to examine the frequency of medical and non-medical use of prescription medications and illicit drugs.
Ethical approval
The Ohio State University Institutional Review Board (IRB) determined that this study was exempt from IRB review (protocols 2014E0530 and 2014E0628).
Results
Participant characteristics
Reflecting the demographics of the local HIV epidemic, the 254 HIV-positive respondents were largely male (91%), aged 40 or older (61%), white (69%), and MSM (85%). Seventy percent of participants had attended at least some college, and 95% were currently taking ART. Although respondents at the two clinics differed by age and education level, sex at birth, ethnicity, sexual orientation, and ART use were similar between the hospital clinic and community clinic (Table 1) .
Medical and non-medical use of prescription medication
Of the six prescription medication categories queried for use in the preceding year, survey respondents at both clinics used opioid pain medications most commonly: 43% overall reported medical use of prescription opioids and 11% reported non-medical use in the last year ( Table 2 ). The frequency of medical and non-medical opioid use in the last year was similar between clinics (medical use, p = .1; non-medical use, p = .3). Use of anti-anxiety medications in the last year was also frequent, with 23% reporting medical use and 8% reporting nonmedical use in the hospital clinic and 41% reporting medical use and 10% reporting non-medical use at the community clinic (hospital vs. community clinic: medical use, p = .01; non-medical use, p = .4). At the hospital clinic, prescription sedatives were reported by 18% and 7% of participants in the last year for medical and nonmedical uses, respectively; prescription sedative use at the community clinic was approximately twice as high, with 43% of respondents reporting medical use and 12% reporting non-medical use of prescription sedatives in the last year (hospital vs. community clinic: medical use, p < .0001; non-medical use, p = .2). Erectile dysfunction medications were used medically by approximately 14% of men in the last year, and non-medically by 9%; erectile dysfunction medication use in the last year did not differ significantly between clinics (medical use, p = .1; nonmedical use, p = .4). Use of stimulants was rare and similar in both sites (hospital vs. community clinic in the last 12 months: medical use, p = .4; non-medical, p = .6). Use of antipsychotic medications was rarely reported by participants at the hospital clinic but was much more frequent at the community clinic (1% vs. 18%, respectively, reported medical use in the last year; p < .0001). Overall in the (3) 0 (0) Missing/refuse to answer 2 (1) 2 (0) 0 (0) a Some participants self-reported more than 1 race, so categories total > 100. b p-Values comparing populations at hospital clinic and community clinic.
previous year, 27% of participants reported non-medical use of any prescription drug: 17% used one medication, 8% used two medications, and 2% used three or more medications.
Not surprisingly, the proportion of respondents endorsing either medical or non-medical use of each prescription medication category was substantially lower when asking about use in the last month, with only about half as many respondents reporting use in the last month compared to the proportion reporting use in the last year (Table 2) . Overall in the past month, 14% of respondents reported non-medical use of at least one prescription medication, with 9% using one medication, 4% using two medications, and less than 1% reporting non-medical use of three or more medications.
Overall, no demographic characteristic, including sex, age, race, sexual orientation, or education, was significantly associated with use of any prescription medication (including medical and non-medical use) in the previous year or month.
Other substance use
Most participants (75%) had used alcohol in the last year. Tobacco use (e.g., cigarettes, cigars and "swishers") in the last year was also common, and differed by site (42% (hospital clinic) vs. 64% (community clinic); p = .003). Use of marijuana, "poppers" (alkyl nitrites), methamphetamines and cocaine was reported more frequently than other illegal drugs. More than a third (37%) reported marijuana use in the last year, including 26% in the preceding month. Poppers were used by 21% of participants overall in the past year, and 15% in the last month ( Table 2) .
Comparison of drug use between clinics
Non-medical use of each prescription medication category in the last year was similar among the hospital and community-clinic respondents. Non-medical use of each prescription medication in the last month was also similar among hospital and community-clinic respondents, with the exception of sedatives, which were used more by community-clinic respondents compared to the hospital clinic respondents (9% vs. 5%; p = .03). Medical use of anxiety medications (12 months, p = .01; 1 month, p = .0006), sedatives (12 months, p < .0001; 1 month, p = .001), and antipsychotic medications (12 months, p < .0001; 1 month, p < .0001) were significantly higher in the community clinic compared to the hospital clinic in both time periods. The community clinic also had a significantly higher use of tobacco (12 months, p = .003; 1 month, p < .0001) and several illicit drugs in both the last year and month: marijuana (12 months, p = .02; 1 month, 
(2) a Denominator for erectile dysfunction medications is restricted to men only (hospital clinic, n = 134; community clinic, n = 93). Note: GHB, Gamma-hydroxybutyrate; MDMA, 3,4-methylenedioxy-methamphetamine. p = .01), methamphetamine (12 months, p = .02; 1 month, p = .04), cocaine (12 months, p = .02), and MDMA (12 months, p = .02; 1 month, p = .047) ( Table 2 ).
Discussion
Among HIV-positive individuals recruited from an academic medical center and a community clinic, we found that beyond the expected high prevalence of use of ART (95%), use of other prescription medications by HIV-positive patients was very common, and use of prescription opioids in both participant populations approached 50%. In the US, sales of opioid pain relievers tripled from 1999 to 2010, from about 2 kg/10,000 people to 7 kg/10,000 people; coincident with this dramatic increase, the rate of opioid-related overdose deaths and treatment admissions almost quadrupled (Centers for Disease Control and Prevention, 2011) . In a nationally representative survey conducted from 2011-2012, 7% of US respondents aged 20 or older had used a prescription opioid in the previous month (Frenk, Porter, & Paulozzi, 2015) . In contrast, we report that 24% of "in care" HIV-positive individuals had used prescription opioids (capturing both medical and non-medical use) in the previous month, more than triple the national average. When the time period was expanded to the previous year, almost half of respondents had been exposed to opioid pain medications.
We found clinic-specific differences in drug and medication use. We suggest that the findings from the hospital clinic sample would be similar to other "in care" HIV-positive populations in the urban US, and the findings from the community clinic are generalizable to other community organizations which provide comprehensive medical, dental, and behavioral health services to HIV-positive individuals in and out of HIV-specific care. Our findings are similar to what has been observed in other studies, including some research from settings that could be considered higher risk than this two-site sample. Prescription opioids treat pain, and in US studies, 39-85% of people living with HIV report pain (Merlin et al., 2014) . In one study of indigent HIV-positive adults in California, 53% had received an opioid prescription in the prior 90 days (Jeevanjee et al., 2014) . In a study of HIV-positive MSM, 14% endorsed recent non-medical use of prescription opioids (Kelly & Parsons, 2010) . We found that 14% of respondents reported non-medical use of at least one prescription medication in the prior month, and 27% in the previous year.
There are several potential clinical implications to these findings. First, as measured by self-report, almost all of the respondents to our survey were taking ART.
Drug-drug interactions between ARTs and some prescription medications have previously been reported. In one study of healthy volunteers, co-administration of ritonavir/lopinavir almost tripled the plasma concentration of oral oxycodone (Nieminen et al., 2010) . Based on this result, other ARTs taken concomitantly with ritonavir could similarly increase oxycodone concentration (Liverpool Drug Interactions Group, 2015) . Second, prescription opioids are linked to subsequent heroin use. In one study, past non-medical use of prescription pain medication was associated with a 19-fold increase in initiation of heroin use. In the same report, nearly 80% of recent heroin initiates reported previous non-medical use of prescription pain relievers (Muhuri, Gfroerer, & Davies, 2013) . Third, owing to similar chemical structures and mechanisms of action (e.g., µ-opioid receptor agonism) between prescription opioids (e.g., oxycodone) and illicit opioid drugs (e.g., heroin), prescription opioids may have similar adverse virological consequences as illicit opioid drugs. In one study of HIV-positive adults, non-medical use of prescription opioids was associated with significantly reduced ART adherence (Jeevanjee et al., 2014) . Other provocative data suggest potential direct links between opioid use and HIV reactivation (Prottengeier, Koutsilieri, & Scheller, 2014) . A very large, methodologically rigorous study comparing HIV-positive and HIV-negative patients linked longterm opioid use with significantly increased mortality, including a 46% increase in HIV-positive patients versus only 25% increase in HIV-negative patients (Weisberg et al., 2015) . These findings need further examination, but suggest that prescription opioids, like illicit opioids (reviewed in Banerjee et al., 2011) , may accelerate HIV disease progression.
Although this study did not attempt to address the relationship between prescription opioid use and medication adherence, the use of non-prescription opioids such as heroin has been linked to adverse biomedical and behavioral outcomes in HIV-positive individuals, including poor antiretroviral therapy (ART) adherence (Azar et al., 2015; Malta, Strathdee, Magnanini, & Bastos, 2008) . Recent cross-sectional research supports a parallel link between non-medical prescription opioid use and ART non-adherence: recent non-medical prescription opioid users had 47% increased odds of self-reported ART non-adherence (Jeevanjee et al., 2014) . In contrast, in another study, those reporting recent medical use of prescription opioids had 39% decreased odds of selfreported ART non-adherence (Surratt et al., 2015) .
Our study had important limitations. First, as a crosssectional survey, we cannot make inferences about the causes and consequences of prescription medication use. Some participants may have misreported their medication use out of stigma or embarrassment, although our design (self-administered and without collection of personal identifiers) was chosen to maximize participant privacy and confidentiality. We also did not ask about dose or frequency of use of any drug, including alcohol. Some participants may have completed the survey more than once, but because no compensation was provided, patients had little incentive to participate multiple times. By design, our findings are generalizable only to "in care" HIV-positive patients, whereas prescription medication use by "out-of-care" HIV patients may be different. We simplified the survey to ease completion by asking about classes of medication (e.g., opioids, stimulants) rather than specific medications. Although participants' ability to answer questions correctly may have been limited by their understanding of medication classes, we tried to mitigate this weakness by giving specific examples of medication names. Finally, we did not test hair or urine specimens to validate self-reported drug use, although such samples are critical for future work that looks to link medication use to biological or behavioral outcomes.
Most respondents to our survey who indicated any prescription medication use reported that they used medications medically instead of non-medically. While this difference may be critical from a legal standpoint, the effects of these medications are likely to be independent of the characterization of their use as medical or non-medical. We suggest that the primary focus on non-medical use of prescription medications not only underestimates the widespread exposure of HIV-positive individuals to prescription drugs, but may also underestimate the behavioral and biological effects of use of prescription medications by this population. We also suggest that it would be prudent for HIV providers to regularly review their opioid prescription practices to make sure that they are appropriate; this review could also help identify patients at risk for opioid dependence and those who may benefit from referral to a pain medicine specialist or addiction medicine specialist.
